Please assess the completion status of the following clinical trial:

Trial Title: Venetoclax and Obinutuzumab for Relapsed/Refractory Primary CNS Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~1. Age at inclusion ≥ 18 to 80 years, in case of ECOG 0 to 1 age up to 85 years~2. Eastern Cooperative Group performance status (ECOG) ≤ 3~3. Evaluable lymphoma manifestation in the CNS, either contrast-enhanced lesion in the brain parenchyma or measurable meningeal lesions.~4. Biopsy proven CD20 positive PCNSL at initial diagnosis or previous relapse/progression (re-biopsy at study inclusion is not mandatory for inclusion, but strongly recommended if time in remission is longer than 24 months).~5. At least one prior HD-MTX containing chemotherapy application (MTX dosed at ≥ 1 g/m2 body surface area) before progression or relapse.~6. Confirmed relapsed or refractory PCNSL according to the IPCG response criteria with the following definition: Evidence of disease recurrence following PR/CR or uCR or no radiological response (SD or PD) as per the IPCG criteria to prior chemotherapy regimen(s), at least one of them containing high-dose methotrexate.~7. Absolute neutrophil count (ANC) of at least 1'500/μl~8. Platelet count of at least 50'000/μl~9. Adequate liver (alanine aminotransferase \[ALAT\] and AST ≤ 3.0 x upper limit of normal \[ULN\] and total bilirubin ≤ 1.5 x ULN) and kidney function (estimated ≥ 30ml/min creatinine clearance according to Cockgroft-Gault formula)~10. Written informed consent~11. Recovery from toxicity from previous anti-lymphoma treatment to ≤ grade 2~Exclusion criteria:~1. Known allergy to venetoclax or other components of the formulation~2. Known allergy to obinutuzumab or other components of the formulation~3. Primary ocular lymphomas without brain parenchymal involvement~4. Lymphoma relapse outside the CNS; extra CNS relapse needs to be ruled out by body CT scans (neck till pelvis) or PET-CT scans.~5. Contraindications for lumbar puncture at the discretion of the clinical investigator~6. Prior exposure to obinutuzumab or venetoclax~7. Other additional anti-lymphoma treatment, e.g. chemotherapy or radiotherapy~8. Active hepatitis B or C~9. HIV seropositivity~10. Chronic use of immunosuppressive drugs, e.g. steroids for systemic autoimmune disease~11. Active infections requiring treatment~12. Other active malignancies (except non-melanoma skin cancer). Prior malignancies without evidence of disease for at least 5 years are allowed~13. Patient is pregnant or breastfeeding, or expecting to conceive or father children within one year of finishing venetoclax and 18 months for obinutuzumab.~14. Prior allogeneic haematopoietic stem cell or solid organ transplantation~15. Therapeutic intervention in setting of other former interventional clinical trial within 30 days before the first IMP administration in VENOBI study; simultaneous participation in registry and diagnostic studies or follow up of an interventional trial is allowed~16. Patient without legal capacity who is unable to understand the nature, significance and consequences of the trial~17. Known or persistent abuse of medication, drugs or alcohol~18. Person who is in a relationship of dependence/employment with the sponsor or the investigator~19. Administration of moderate or strong CYP3A inhibitors or inducers within 1 week of initiation of venetoclax dosing.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Dosing group 1 (Type: EXPERIMENTAL): Venetoclax 600mg + Obinutuzumab 1000mg
- Dosing group 2 (Type: EXPERIMENTAL): Venetoclax 800mg + Obinutuzumab 1000mg
- Dosing group 3 (Type: EXPERIMENTAL): Venetoclax 1000mg + Obinutuzumab 1000mg

Based on this trial design, predict the completion outcome and termination type (if applicable).